Prediction of Sustained Virological Response to Telaprevir-Based Triple Therapy Using Viral Response within 2 Weeks.
about
Simeprevir-Based Triple Therapy with Reduced Doses of Pegylated Interferon α-2a Plus Ribavirin for Interferon Ineligible Patients with Genotype 1b Hepatitis C Virus.The Role of Hepatitis C Virus Core Antigen Testing in the Era of Direct Acting Antiviral Therapies: What We Can Learn from the Protease InhibitorsThe Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients.
P2860
Prediction of Sustained Virological Response to Telaprevir-Based Triple Therapy Using Viral Response within 2 Weeks.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Prediction of Sustained Virolo ...... Viral Response within 2 Weeks.
@ast
Prediction of Sustained Virolo ...... Viral Response within 2 Weeks.
@en
Prediction of Sustained Virolo ...... Viral Response within 2 Weeks.
@nl
type
label
Prediction of Sustained Virolo ...... Viral Response within 2 Weeks.
@ast
Prediction of Sustained Virolo ...... Viral Response within 2 Weeks.
@en
Prediction of Sustained Virolo ...... Viral Response within 2 Weeks.
@nl
prefLabel
Prediction of Sustained Virolo ...... Viral Response within 2 Weeks.
@ast
Prediction of Sustained Virolo ...... Viral Response within 2 Weeks.
@en
Prediction of Sustained Virolo ...... Viral Response within 2 Weeks.
@nl
P2093
P2860
P356
P1476
Prediction of Sustained Virolo ...... Viral Response within 2 Weeks
@en
P2093
Hisanobu Deguchi
Izumi Inoue
Junya Nuta
Kosaku Moribata
Masao Ichinose
Mikitaka Iguchi
Naoki Shingaki
Ryo Shimizu
Shuya Maeshima
Takao Maekita
P2860
P304
P356
10.1155/2014/748935
P577
2014-09-28T00:00:00Z